According to the Legislative Budget Board (LBB), HB 4454 will have no significant fiscal implications for the State. This assessment applies to both the establishment of the Task Force on Patient Solicitation and the enforcement mechanisms included in the bill. It reflects the assumption that relevant state agencies—such as the Health and Human Services Commission (HHSC), the Office of the Attorney General (OAG), and the state court system—will be able to implement the bill’s provisions using existing resources and administrative capacity.

Specifically, although the bill mandates the creation of a task force composed of appointed experts and calls for interagency collaboration and reporting requirements, these responsibilities are not expected to generate costs that would require additional appropriations. The bill also amends sections of the Health and Safety Code and Occupations Code to tighten regulations around patient solicitation and advertising, but it does not introduce new programs requiring substantial funding.

From a local government perspective, the fiscal note likewise projects no significant fiscal impact. While local law enforcement and judicial entities may engage in enforcement activities associated with the bill’s updated provisions, such involvement is not anticipated to be financially burdensome or substantially different from existing operations.

In summary, HB 4454 is expected to advance its regulatory objectives—namely, enhancing oversight of unethical patient solicitation and deceptive marketing practices—without imposing meaningful new costs on state or local governments.

While the bill’s stated purpose, protecting patients from fraud and manipulation, is well-intentioned, it ultimately raises several significant concerns related to liberty principles and effective governance.

Individual Liberty and Free Enterprise are impacted by the bill’s broad and restrictive approach to regulating health care advertising and referral practices. The legislation imposes vague and expansive language that could capture legitimate marketing efforts or contractual partnerships under the umbrella of illegal solicitation. The prohibition against contracting with marketing providers that generate patient leads unless specific disclosures are made could suppress otherwise lawful business models and entrepreneurial innovations, particularly for small or emerging providers trying to compete with larger institutions. Similarly, restrictions on advertising content and website linkages—such as barring unverified claims or automatically disqualifying certain referrals—may infringe on commercial speech in ways that are not narrowly tailored to combat fraud.

Further, the bill continues a trend of expanding criminal penalties for conduct that could arguably be better addressed through civil enforcement or regulatory compliance. Although the final version of the bill softened some of the original felony enhancements, it still increases civil penalties and empowers prosecutors to bring injunctive actions for violations that may lack criminal intent. Lawmakers who advocate for criminal justice reform or oppose the proliferation of criminal statutes may find these provisions excessive. Texas already has numerous statutes addressing healthcare fraud and deceptive practices, both at the state and federal levels. The bill may introduce redundancy without a clear demonstration that existing tools are inadequate.

Additionally, the creation of a new task force attached to the Health and Human Services Commission represents a potential bureaucratic expansion that duplicates the responsibilities of current oversight bodies. There is no guarantee that the task force’s findings will translate into policy changes, and its formation may divert resources from more targeted regulatory improvements. A more conservative or limited government approach would focus on ensuring better enforcement of existing laws, rather than establishing a new body to propose more regulation.

In sum, while HB 4454 aims to protect patients, it does so by restricting market dynamics, expanding regulatory reach, and imposing broad restrictions on commercial activity. The bill undermines free enterprise, encroaches on private contractual freedoms, and grows the government’s role in managing speech and business relationships in health care. As such, Texas Policy Research recommends that lawmakers vote NO on HB 4454.

• Individual Liberty: The bill impacts individual liberty by placing new restrictions on how patients may receive information and make choices regarding mental health and chemical dependency services. While its intent is to shield individuals from deceptive or exploitative marketing, it may also reduce their exposure to treatment options by limiting outreach strategies used by providers. For example, a prospective patient may benefit from learning about services through lead-generation tools or third-party referrals—tools that are curtailed under this bill unless strict disclosures are met. In its effort to protect, the bill may inadvertently reduce autonomy by substituting state-defined advertising standards for personal decision-making.
• Personal Responsibility: The bill shifts responsibility away from individuals and toward state oversight in preventing exploitation, particularly by expanding penalties and creating a new task force to police marketing practices. While curbing predatory behavior is laudable, the bill could undermine the notion that individuals can and should make informed decisions about their care. It reflects a paternalistic approach in which the state assumes a gatekeeping role in patient-provider interactions, thereby limiting the individual’s responsibility to assess claims, research services, and discern trustworthy care.
• Free Enterprise: This bill imposes significant new limitations on how businesses in the behavioral health and recovery space can advertise, form partnerships, and attract clients. Restrictions on contracting with marketing firms, lead generators, and referral sources create barriers to entry and suppress innovation in competitive outreach. The prohibition of marketing partnerships that are not disclosed in highly specific ways places a regulatory burden on legitimate businesses and may benefit only large, well-resourced providers that can afford legal compliance teams. This tilts the playing field against smaller or rural mental health providers and stifles competition.
• Private Property Rights: There is a moderate impact on private property rights, particularly for business owners operating recovery residences, treatment facilities, or advertising firms. The bill dictates not only what services can be marketed and how, but also who may lawfully be compensated in the process. These constraints may interfere with contractual freedoms and the right to lawfully use property, physical or intellectual, for commerce. While the state has a valid interest in preventing fraud, the bill’s broad reach may criminalize otherwise legitimate business practices without sufficient evidence of harm.
• Limited Government: The creation of a new task force and the expansion of civil and criminal penalties reflect a departure from the principle of limited government. Rather than improving the enforcement of existing statutes through administrative efficiency or transparency, the bill adds a new layer of bureaucracy and regulation. It effectively empowers the state to take a more aggressive role in determining which business practices are acceptable in health care marketing, despite existing laws already addressing fraud and misrepresentation. This trend of expanding the state’s investigatory and prosecutorial footprint raises concerns about government overreach into private sector operations.